Literature DB >> 25127329

Studying progression from glucose intolerance to type 2 diabetes in obese children.

Irina A Dubinina1, Dimitry A Chistiakov2, Irina A Eremina1, Alexei N Brovkin3, Lyubov I Zilberman1, Alexei G Nikitin3, Tamara L Kuraeva1, Valery V Nosikov3, Valentina A Peterkova1, Ivan I Dedov1.   

Abstract

AIM: Identification of metabolic and genetic factors capable to mediate progression from normal glucose tolerance (NGT) through impaired glucose tolerance (IGT) to type 2 diabetes (T2D) in childhood obesity. PATIENTS AND METHODS: Three groups of obese children with NGT (n=54), IGT (n=35), and T2D (n=62) were evaluated. A control group of non-obese normal children (n=210) was also studied. In obese patients, an oral glucose tolerance test (OGTT) was performed. Insulin resistance (IR) was assessed using HOMA-IR index. Insulin sensitivity (IS) was assessed according to the Matsuda formula. Genomic DNA from obese and control children was genotyped for genetic variants of PPARG, ADIPOQ, ADIPOR1, FTO, TCF7L2, and KCNJ11 using a real-time PCR strategy. The unpaired Student's t-test and Kruskal-Wallis one-way test were used to compare quantitative data in two and more groups. To assess the extent to which the various genetic variants were associated with pathology, ORs (odds ratios) and 95% CI (confidence interval) were estimated.
RESULTS: In T2D children, HOMA-IR value (7.5±3.1) was significantly (P<0.001) higher than that in IGT (4.21±2.25) and NGT (4.1±2.4) subjects. The Matsuda IS index was significantly increased in normoglycemic patients compared to IGT individuals (2.8±1.75 vs. 2.33±1.2, P<0.05). The Pro12Ala polymorphism of PPARG was significantly associated with obesity (OR=1.74, 95% CI=1.19-2.55, P=0.004) and T2D in obesity (OR=2.01, 95% CI=1.24-3.26, P=0.004).
CONCLUSION: IR is a major risk factor that mediates progression from NGT to clinical T2D in Russian obese children. This progression may be genetically influenced by the Pro12Ala variant of PPARG.
Copyright © 2014 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Glucose tolerance; Insulin resistance; Insulin sensitivity; Obesity; PPARG

Mesh:

Substances:

Year:  2014        PMID: 25127329     DOI: 10.1016/j.dsx.2014.07.002

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  6 in total

Review 1.  Pharmacogenetic studies update in type 2 diabetes mellitus.

Authors:  Shalini Singh; Kauser Usman; Monisha Banerjee
Journal:  World J Diabetes       Date:  2016-08-10

2.  A Genetic Risk Score Improves the Prediction of Type 2 Diabetes Mellitus in Mexican Youths but Has Lower Predictive Utility Compared With Non-Genetic Factors.

Authors:  América Liliana Miranda-Lora; Jenny Vilchis-Gil; Daniel B Juárez-Comboni; Miguel Cruz; Miguel Klünder-Klünder
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-12       Impact factor: 5.555

3.  Genotype Phenotype Correlation of Genetic Polymorphism of PPAR Gamma Gene and Therapeutic Response to Pioglitazone in Type 2 Diabetes Mellitus- A Pilot Study.

Authors:  S Shanmuga Priya; Ramalingam Sankaran; Sudha Ramalingam; Thiagarajan Sairam; L S Somasundaram
Journal:  J Clin Diagn Res       Date:  2016-02-01

Review 4.  Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?

Authors:  Attila Pap; Ixchelt Cuaranta-Monroy; Matthew Peloquin; Laszlo Nagy
Journal:  Int J Mol Sci       Date:  2016-07-30       Impact factor: 5.923

5.  Carbohydrate status in patients with phenylketonuria.

Authors:  María L Couce; Paula Sánchez-Pintos; Isidro Vitoria; María-José De Castro; Luís Aldámiz-Echevarría; Patricia Correcher; Ana Fernández-Marmiesse; Iria Roca; Alvaro Hermida; Miguel Martínez-Olmos; Rosaura Leis
Journal:  Orphanet J Rare Dis       Date:  2018-06-27       Impact factor: 4.123

6.  Ellisras Longitudinal Study 2017: association of hypertension with increasing levels of adiposity in 10- to 14-year-old boys and girls in the Eastern Cape (ELS 31).

Authors:  A Chungag; C M Tata; C R Sewani-Rusike; W Nel; B N Nkeh-Chungag
Journal:  Cardiovasc J Afr       Date:  2019 Sep/Oct       Impact factor: 1.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.